Review

anti-myosin heavy chain type i (Developmental Studies Hybridoma Bank)

Developmental Studies Hybridoma Bank is a verified supplier

Developmental Studies Hybridoma Bank manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Developmental Studies Hybridoma Bank anti-myosin heavy chain type i
Anti Myosin Heavy Chain Type I, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 97/100, based on 674 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myosin+type+i/anti-Myosin+heavy+chain+Type+I/custom%40ba%2Ed5%4041819653
Average 97 stars, based on 674 article reviews

anti-myosin heavy chain type i - by Bioz Stars, 2026-10

97/100 stars

Images

Staining:

Article Title: The breaking and making of healthy adult human skeletal muscle in vivo
Article Snippet: .. Sections were stained with various combinations of antibodies against laminin, CD56, desmin and embryonic myosin (F1.652; Developmental Studies Hybridoma Bank); neonatal myosin (NCL-MHCn; Novocastra, Leica Microsystems A/S, Ballerup, Denmark); alpha-sarcoglycan (NCL-L-a-SARC, Novocastra); beta-dystroglycan (NCL-L-a-SARC, Novocastra); myogenin (F5d, Developmental Studies Hybridoma Bank); nestin, CD68, collagen IV and dystrophin (cat. no. D8168, Sigma-Aldrich Denmark A/S, Copenhagen, Denmark); myosin type I (BA.D5, Developmental Studies Hybridoma Bank) and myosin type II (A4.74, Developmental Studies Hybridoma Bank). ..

Article Title: The breaking and making of healthy adult human skeletal muscle in vivo.
Article Snippet: .. Sections were stained with various combinations of antibodies against laminin, CD56, desmin and embryonic myosin (F1.652; Developmental Studies Hybridoma Bank); neonatal myosin (NCL-MHCn; Novocastra, Leica Microsystems A/S, Ballerup, Denmark); alpha-sarcoglycan (NCL-L-a-SARC, Novocastra); beta-dystroglycan (NCL-L-a-SARC, Novocastra); myogenin (F5d, Developmental Studies Hybridoma Bank); nestin, CD68, collagen IV and dystrophin (cat. no. D8168, Sigma-Aldrich Denmark A/S, Copenhagen, Denmark); myosin type I (BA.D5, Developmental Studies Hybridoma Bank) and myosin type II (A4.74, Developmental Studies Hybridoma Bank). ..

Article Title: Exercise training during chemotherapy preserves skeletal muscle fiber area, capillarization, and mitochondrial content in patients with breast cancer.
Article Snippet: Coverslips were placed on Pax7 and CD31 stained slides using Vectashield mounting medium containing DAPI (H-1200; Vector Laboratories, Burlingame, CA, USA). .. For fiber type–specific fiber size analysis, muscle sectionswere blocked in bovine serum albumin (2%) and stained at 4°C overnight with primary antibodies for laminin (1:1000, L9393; MilliporeSigma, St. Louis, MO, USA), myosin type I (1:100, BA-F8; Developmental Studies Hybridoma Bank, Iowa City, IA, USA), and myosin type IIA (1:100, SC-71; Developmental Studies Hybridoma Bank). .. The following appropriate fluorescent secondary antibodies were then added to the tissue sections: goat anti-mouse IgG1 568 (1:300, A-21124; Thermo Fisher Scientific), goat anti-mouse IgG2b 488 (1:300, A21141; Thermo Fisher Scientific), and donkey anti-rabbit 633 (1:200, A-21070; Thermo Fisher Scientific).

Double Staining:

Article Title: Sequenced response of extracellular matrix deadhesion and fibrotic regulators after muscle damage is involved in protection against future injury in human skeletal muscle
Article Snippet: Intermediate filament and sarcolemma disruption was investigated by double-staining with primary antibodies for desmin (18-0016; Zymed, San Francisco, CA, USA) and dystrophin (ab15277; Abcam), respectively. .. Regeneration was investigated by double-staining serial sections with the following combinations of primary antibodies: embryonic myosin (F1.652; Developmental Studies Hybridoma Bank, Iowa City, IA, USA) and dystrophin; CD56 (347740; Becton Dickinson, San Jose, CA, USA) and laminin; laminin α5 (4C7, ab17107; Abcam) and laminin; myosin type I (A4.951; Developmental Studies Hybridoma Bank) and laminin; myosin type II (A4.74; Developmental Studies Hybridoma Bank) and laminin. .. Tenascin-C immunoreactivity was digitally evaluated from sections incubated with the primary antibody NCL-Tenas-C (Novocastra; Leica Microsystems, Newcastle On Tyne, UK), a biotinylated secondary antibody (E0433; Dako), Vector Elite ABC kit (PK6100; Vector Laboratories, Peterborough, UK) and visualized with Immpact diaminobenzidine (DAB) substrate (SK-4105, Vector Laboratories).

other:

Article Title: Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice.
Article Snippet: Bone Research (2026) 14:30 Immunostaining was performed with the bond detection kit (DS9800, Leica) on Leica Biosystems BOND RX.

Article Title: Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice
Article Snippet: Slides with rehydrated samples were immersed in TRAP staining solution mix and incubated with Naphthol AS-MX Phosphate Substrate mix (Napthol AS-MX Phosphate N-4875, Sigma; Ethoxyethanol 128082, Merck) and Fast Red Violet LB Salt (HY-D1491A, MedChemTronica Sollentuna, Sweden) at 37 °C in a water bath for 1 h. Slides were then rinsed with distilled water as described.

Article Title: Exercise training during chemotherapy preserves skeletal muscle fiber area, capillarization, and mitochondrial content in patients with breast cancer
Article Snippet: On the next day, sections were incubated in Alexa Fluor goat anti-rabbit 488 (A-11008; Thermo Fisher Scientific) for 30 min. Endothelial cells were identified using an FITCCD31 antibody (1:100, 561813; BD Biosciences, San Jose, CA, USA).

Image Search Results

(A) Representative magnetic resonance imaging (MRI) of the thigh and quadriceps muscle cross-sectional area (CSA) assessed by MRI (controls: n = 17; HSCT: n = 11). (B) Representative DXA scan and whole-body, and leg, lean mass assessed by DXA (controls: n = 27; HSCT: n = 17). (C) Whole-body bone mineral density and Z-scores assessed by DXA (controls: n = 27; HSCT: n = 17). (D) Isometric maximal voluntary contraction (MVC) measured by dynamometry, presented as Isometric MVC and Specific force (normalized to body weight) (controls: n = 28; HSCT: n = 18). Rate of force development (RFD) was also measured by dynamometry (controls: n = 11; HSCT: n = 7). (E) Physical function assessed using the 30-s chair-stand test, timed up-and-go test, and 6-min walk test (controls: n = 17; HSCT: n = 11). F-K. Data from muscle biopsy immunofluorescence, analyzed by two-way repeated-measures ANOVA with factors Group and Sex. Data are displayed as individual values with mean ± SD. Men are represented by circles, women by squares (controls: n = 26; HSCT: n = 16). (F) Muscle biopsy cross-section stained by immunofluorescence with the basement membrane marker laminin, delineating the muscle fiber borders, and type I myosin heavy chain (MyHC I). The unstained (black) fibers were designated type II fibers. Scale bar = 100 μm. Such images were used to calculate fiber type-specific data for G) fiber type distribution (proportion and relative area), H) shape factor index, I) fiber cross-sectional area (CSA), J) myonuclear content, K) myonuclear domain size. A-E. Data were analyzed with unpaired two-tailed t-tests.

Journal: medRxiv

Article Title: Single-Nucleus to Whole Body Phenotyping Reveals Neuromuscular Impairment and Preserved Exercise Adaptations in Long-Term Pediatric HSCT Survivors >10 years after treatment

doi: 10.64898/2026.04.24.26351644

Figure Lengend Snippet: (A) Representative magnetic resonance imaging (MRI) of the thigh and quadriceps muscle cross-sectional area (CSA) assessed by MRI (controls: n = 17; HSCT: n = 11). (B) Representative DXA scan and whole-body, and leg, lean mass assessed by DXA (controls: n = 27; HSCT: n = 17). (C) Whole-body bone mineral density and Z-scores assessed by DXA (controls: n = 27; HSCT: n = 17). (D) Isometric maximal voluntary contraction (MVC) measured by dynamometry, presented as Isometric MVC and Specific force (normalized to body weight) (controls: n = 28; HSCT: n = 18). Rate of force development (RFD) was also measured by dynamometry (controls: n = 11; HSCT: n = 7). (E) Physical function assessed using the 30-s chair-stand test, timed up-and-go test, and 6-min walk test (controls: n = 17; HSCT: n = 11). F-K. Data from muscle biopsy immunofluorescence, analyzed by two-way repeated-measures ANOVA with factors Group and Sex. Data are displayed as individual values with mean ± SD. Men are represented by circles, women by squares (controls: n = 26; HSCT: n = 16). (F) Muscle biopsy cross-section stained by immunofluorescence with the basement membrane marker laminin, delineating the muscle fiber borders, and type I myosin heavy chain (MyHC I). The unstained (black) fibers were designated type II fibers. Scale bar = 100 μm. Such images were used to calculate fiber type-specific data for G) fiber type distribution (proportion and relative area), H) shape factor index, I) fiber cross-sectional area (CSA), J) myonuclear content, K) myonuclear domain size. A-E. Data were analyzed with unpaired two-tailed t-tests.

Article Snippet: For fiber type–specific morphology and fiber type distribution, sections were stained with MyHC I (BA.D5; DSHB) and laminin (L9393; Sigma-Aldrich).

Techniques: Magnetic Resonance Imaging, Immunofluorescence, Staining, Membrane, Marker, Two Tailed Test

A: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes that were treated during differentiation with various NSAIDs, including aspirin (ASA), indomethacin (INDO), ibuprofen (IBU), celecoxib, and SC-236 at the indicated concentrations. Cells were stained for myosin heavy chain (MyHC, green), myogenin (MyoG, red), and DAPI (nuclei, blue). B: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes treated with doses of INDO ranging from 6.25 µM to 400 µM. C-E : Quantitative analysis of INDO-treated cells showing a dose-dependent decrease in DAPI + cell density ( C ), differentiation index (%) ( D ), and myotube area (%) ( E ). F: Representative images of ASA-treated myotubes ranging from 62.5 µM to 4 mM. H–J: Quantification of DAPI + cell density ( H ), differentiation index (%) ( I ), and myotube area (%) ( J ) in C2C12 cells receiving ASA treatment. K: Representative images comparing the effects of ASA (2 mM), INDO (200 µM), and the combination of INDO + ASA on C2C12 myotube morphology. L-N: Statistical comparison of cell density ( L ), differentiation index (%) ( M ), and myotube area (%) ( N ) across vehicle and treatment groups. Data are expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Holm-Šídák post hoc tests. *, **, ***, and **** denotes p<0.05, p<0.01, p<0.001, and p<0.0001 between indicated groups, respectively. # denotes p<0.05 difference between ASA and vehicle groups.

Journal: bioRxiv

Article Title: Aspirin hastens resolution of skeletal muscle inflammation and promotes recovery of muscle strength following acute injury

doi: 10.64898/2026.04.21.719989

Figure Lengend Snippet: A: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes that were treated during differentiation with various NSAIDs, including aspirin (ASA), indomethacin (INDO), ibuprofen (IBU), celecoxib, and SC-236 at the indicated concentrations. Cells were stained for myosin heavy chain (MyHC, green), myogenin (MyoG, red), and DAPI (nuclei, blue). B: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes treated with doses of INDO ranging from 6.25 µM to 400 µM. C-E : Quantitative analysis of INDO-treated cells showing a dose-dependent decrease in DAPI + cell density ( C ), differentiation index (%) ( D ), and myotube area (%) ( E ). F: Representative images of ASA-treated myotubes ranging from 62.5 µM to 4 mM. H–J: Quantification of DAPI + cell density ( H ), differentiation index (%) ( I ), and myotube area (%) ( J ) in C2C12 cells receiving ASA treatment. K: Representative images comparing the effects of ASA (2 mM), INDO (200 µM), and the combination of INDO + ASA on C2C12 myotube morphology. L-N: Statistical comparison of cell density ( L ), differentiation index (%) ( M ), and myotube area (%) ( N ) across vehicle and treatment groups. Data are expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Holm-Šídák post hoc tests. *, **, ***, and **** denotes p<0.05, p<0.01, p<0.001, and p<0.0001 between indicated groups, respectively. # denotes p<0.05 difference between ASA and vehicle groups.

Article Snippet: Primary antibodies used include MyHC type I [Developmental Studies Hybridoma Bank (DSHB), BA-D5c, 1:100], MyHC type IIA (DSHB, SC-71c, 1:100), MyHC type IIB (DSHB, BF-F3c, 1:100), eMHC (DSHB, F1.652s, 1:20), Ly6G (GR1) (Bio-Rad, MCA2387, 1:50), CD68 (Bio-Rad, MCA1957, 1:200), CD206 (Bio-Rad, MCA2387, 1:50), and laminin (Abcam, ab7463, 1:200).

Techniques: Immunofluorescence, Staining, Comparison

Journal: bioRxiv

Article Title: Aspirin hastens resolution of skeletal muscle inflammation and promotes recovery of muscle strength following acute injury

doi: 10.64898/2026.04.21.719989

Figure Lengend Snippet: A: Force-frequency curves showing maximal isometric tetanic force generated by the TA muscle in situ at day 14 post-injury. B: Total area under the force-frequency curve (absolute muscle strength). C-D: Specific force-frequency curves ( C ) and specific force-frequency area under the curve ( D ) (relative muscle strength) normalized to muscle size. E: Representative histological and immunofluorescence images of muscle cross-sections. Top: H & E staining; Middle: Actin (red), DAPI (blue), and Laminin (LAM, white); Bottom: Fiber type staining for type I (blue), type IIA (green), type IIX (black), and type IIX (red), and laminin (white). F-H: Quantification of regenerative maturation markers including the percentage of centrally nucleated myofibers ( F ), fibers with ≥2 central nuclei ( G ), and fibers with ≥3 central nuclei ( H ). I-J: Mean myofiber cross-sectional area (CSA) ( I ) and muscle fiber type profile (I, IIA, IIX, IIB) ( J ). Data are presented as mean ± SEM. For force-frequency curves statistical significance was determined by two-way ANOVA followed by Holm-Šídák post hoc tests. * denotes p<0.05 vs. uninjured control mice (CON), # denotes p<0.05 vs. injured mice receiving VEH, and $ denotes p<0.05 vs. injured mice receiving ASA. For bar graphs, different letters indicate significant differences (p<0.05) by one-way ANOVA with Holm-Šídák post hoc tests.

Techniques: Generated, In Situ, Immunofluorescence, Staining, Control

Skeletal muscle size and force characterization of tamoxifen‐inducible skeletal muscle‐specific Unc45b knockout mice. (A) Quantification of UNC45B expression in gastrocnemius muscle, soleus muscle, plantaris muscle, diaphragm, and heart in Unc45b flox/flox mice and ACTA1‐MerCreMer; Unc45b flox/flox mouse 8 weeks after tamoxifen injection. (B) Representative western blots for UNC45B. (C) UNC45B expression. (D) Body weight. Relative mass of the (E) gastrocnemius and (F) soleus muscles, expressed as a ratio to body weight. (G) Grip strength normalized to body weight. (H) Plantar flexor torque. (I) Plantar flexor torque normalized to triceps surae muscle mass. (J) Representative images of gastrocnemius muscle. Scale bar set to 50 μm. CSA of (K) type I, (L) type IIa, (M) type IIx, and (N) type IIb fibers in gastrocnemius muscle. (O) Representative images of soleus muscle. Scale bar set to 50 μm. CSA of (P) type I, (Q) type IIa, (R) type IIx, and (S) type IIb fibers in soleus muscle. (T) Representative western blots. (U) Myosin expression. Data are shown as means and individual values ± standard error (2 weeks, n = 6; 4 weeks, n = 6; 8 weeks, n = 6). Different letters indicate significant differences between groups. BW, body weight; fCSA, fiber cross‐sectional area; GAS, gastrocnemius; SOL, soleus; Unc45b imKO, inducible skeletal muscle‐specific Unc45b knockout.

Journal: Aging Cell

Article Title: UNC45B Reduction With Aging: A Myofiber‐Intrinsic Promoting Factor for Sarcopenia

doi: 10.1111/acel.70502

Figure Lengend Snippet: Skeletal muscle size and force characterization of tamoxifen‐inducible skeletal muscle‐specific Unc45b knockout mice. (A) Quantification of UNC45B expression in gastrocnemius muscle, soleus muscle, plantaris muscle, diaphragm, and heart in Unc45b flox/flox mice and ACTA1‐MerCreMer; Unc45b flox/flox mouse 8 weeks after tamoxifen injection. (B) Representative western blots for UNC45B. (C) UNC45B expression. (D) Body weight. Relative mass of the (E) gastrocnemius and (F) soleus muscles, expressed as a ratio to body weight. (G) Grip strength normalized to body weight. (H) Plantar flexor torque. (I) Plantar flexor torque normalized to triceps surae muscle mass. (J) Representative images of gastrocnemius muscle. Scale bar set to 50 μm. CSA of (K) type I, (L) type IIa, (M) type IIx, and (N) type IIb fibers in gastrocnemius muscle. (O) Representative images of soleus muscle. Scale bar set to 50 μm. CSA of (P) type I, (Q) type IIa, (R) type IIx, and (S) type IIb fibers in soleus muscle. (T) Representative western blots. (U) Myosin expression. Data are shown as means and individual values ± standard error (2 weeks, n = 6; 4 weeks, n = 6; 8 weeks, n = 6). Different letters indicate significant differences between groups. BW, body weight; fCSA, fiber cross‐sectional area; GAS, gastrocnemius; SOL, soleus; Unc45b imKO, inducible skeletal muscle‐specific Unc45b knockout.

Article Snippet: The primary antibodies used in this study were as follows: mouse anti‐myosin heavy chain type I (1:50, BA‐D5, DSHB, IA, USA), anti‐myosin heavy chain type IIa (1:200, SC‐71, DSHB), anti‐myosin heavy chain type IIb (1:100, BF‐F3, DSHB), anti‐Laminin (1:200, L9393, Sigma‐Aldrich), anti‐MYH1 (1:200, M4276, Sigma‐Aldrich), and anti‐Laminin‐2 (1:400, L0663, Sigma‐Aldrich).

Techniques: Knock-Out, Expressing, Injection, Western Blot, Muscles